Tarceva Related Clinical Trials
Erlotinib (Tarceva) vs. Standard Chemotherapy (Paclitaxel and Carboplatin) in Patients With Advanced NSCLC and ECOG PS 2 [Active, not recruiting]
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients [Active, not recruiting]
Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer [Recruiting]
Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma [Recruiting]
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer [Completed]
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma [Active, not recruiting]
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. [Completed]
Tarceva and Capecitabine for Pancreatic Cancer [Active, not recruiting]
Tarceva® as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC [Recruiting]
Phs. II Study of OSI-774 (Erlotinib, Tarceva) in Elderly Patients W/Advanced Stage or Inoperable Non-Small Cell Lung Cancer (NSCLC) [Suspended]
Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer [Completed]
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer [Active, not recruiting]
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function [Completed]
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens [Active, not recruiting]
Clinical Trial to Test the Safety and Effectiveness of an Investigational Drug CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer [Recruiting]
Trial of Letrozole Plus OSI-774 (Tarceva) in Post-Menopausal Women With Estrogen Receptor (ER) and/or Progesterone Receptor (PR)-Positive Metastatic Breast Cancer [Recruiting]
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer [Completed]
Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced NSCLC in Patients With Mutations in the TK Domain of EGFR [Recruiting]
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma [Recruiting]
Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma [Active, not recruiting]
Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) [Recruiting]
Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma [Recruiting]
A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer) [Active, not recruiting]
Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma [Recruiting]
A Phase II Study of ACZONEâ„¢ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash [Terminated]
Ph I Dasatinib + Erlotinib in Recurrent MG [Recruiting]
Neoadjuvant Erlotinib (Tarceva) in Transitional Cell Carcinoma [Recruiting]
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer [Active, not recruiting]
Phase I Chemoprevention Trial With Green Tea Polyphenon E and Erlotinib in Patients With Premalignant Lesions of the Head and Neck [Recruiting]
A Study of 7 Day's of Erlotinib Before Surgery, Followed by After Surgery Erlotinib-gemcitabine in Patients With Pancreatic Cancer [Recruiting]
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer [Recruiting]
Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar [Recruiting]
Study of Erlotinib (Tarceva�) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene [Recruiting]
Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2 [Recruiting]
Tarceva With Chemoradiation and Adjuvant Chemotherapy for Resectable Pancreatic Cancer [Recruiting]
Phase I/II Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers [Recruiting]
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations [Recruiting]
Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer [Recruiting]
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma [Recruiting]
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer [Recruiting]
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer. [Recruiting]
A Study of First-line Maintenance Tarceva (Erlotinib) Versus Tarceva at Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer After Chemotherapy [Recruiting]
Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) [Recruiting]
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva�), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy [Recruiting]
Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib [Not yet recruiting]
Erlotinib Prior to Surgery in Patients With Head and Neck Cancer [Recruiting]
OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas [Not yet recruiting]
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer [Recruiting]
Erlotinib and Temsirolimus for Solid Tumors [Recruiting]
EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation [Recruiting]
2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC) [Recruiting]
Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer [Recruiting]
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma [Recruiting]
Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations [Recruiting]
Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer [Recruiting]
Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib [Not yet recruiting]
Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen [Recruiting]
A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS) [Recruiting]
Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT) [Recruiting]
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy [Recruiting]
FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer [Not yet recruiting]
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung [Recruiting]
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib [Recruiting]
Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck [Recruiting]
Erlotinib Prevention of Oral Cancer (EPOC) [Recruiting]
A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [Recruiting]
BATTLE Program: Tarceva and Targretin in Patients With NSCLC [Recruiting]
BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC [Recruiting]
Study of Non-Small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-Based Treatment [Recruiting]
Study of Tarceva and Targretin in Stage I-II Lung Cancer [Recruiting]
Phase II Trial of Erlotinib in Advanced Pancreatic Cancer [Recruiting]
Neoadjuvant, Tarceva, Surgery for Non-Small Cell Lung Cancer (NSCLC) [Recruiting]
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy. [Recruiting]
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) [Recruiting]
A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 NSCLC [Recruiting]
Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy [Recruiting]
A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma [Recruiting]
Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer [Recruiting]
Erlotinib and Chemotherapy for Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON) [Recruiting]
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery [Recruiting]
TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer [Recruiting]
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) [Recruiting]
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC [Recruiting]
Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery [Recruiting]
Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-Positive 'Triple Receptor-Negative' Breast Cancer [Recruiting]
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma [Recruiting]
Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer [Recruiting]
Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer [Recruiting]
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme [Recruiting]
A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone [Recruiting]
Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer [Recruiting]
Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC) [Recruiting]
Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer [Recruiting]
A Phase 1 Dose-Escalation Study of OSI-906 and Erlotinib (Tarceva®) [Recruiting]
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA) [Recruiting]
Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer [Recruiting]
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer [Recruiting]
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) [Recruiting]
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer [Recruiting]
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib [Recruiting]
MATER Study: A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash [Recruiting]
|
